Leading by U.S. and Chinese experts and scientists, Tarcine Biotech (Hong Kong) Ltd. developed NPCheckTM ELISA Kits for clinical application successfully.

NPCheckTM qualitative and quantitative ELISA kits are manufactured by a GMP plant. They are used for screening, early diagnosis and monitoring after the treatment of nasopharyngeal cancer (NPC) by detecting Rta IgG in serum. NPCheckTM owns a number of Chinese patents, and has authorized CFDA certificate since 2009. Having reviewed the data of various clinical research centers from Guangdong, Guangxi, Fujian and Sichuan, the results were compliance to biopsy of pathophysiology. The average sensitivity and specificity were 89.3% and 94.4% respectively.